Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Evgeniya Ranneva

Evgeniya Ranneva

Skin Tech Pharma Group, Spain

Title: New medical approach for rejuvenation of the periorbital area

Biography

Biography: Evgeniya Ranneva

Abstract

Medical device CE class III is a new potential synergistic treatment for circles under the eyes and lymphedema. It is injection into the tear trough area, palpebral malar groove and upper eyelid. The main medical proposal for this new therapeutic approach is to minimize side effects during long-term therapy and be effective and save. The most common treatment option in the periorbital area is with cross linked Hyaluronic Acid (HA) and therefore, it is important to be aware of the usual complications such as swelling by overcorrection, nodules and edema by compression of lymphatic system. Every ampoule of 1.5 mL contains 5.0 mg/mL of non cross linked HA associated with active biorevitalization solution (BS 27.3 mg/mL) and helps improving the transport function of the actives from biorevitalization solution. The complex actives of BS are: Antioxidants, flavonoids, saponins, polyphenols, peptides and trace element. The results of the study indicate that injections of this product applied on the tear trough, the palpebral malar groove and also the upper eyelid area is a safe and effective treatment with minimum side effects. Medical device CE class III does not cause edema has no overcorrection issues and neither Tyndall effect. The best efficacy was observed in case of volume loss on the area of tear trough and palpebromalar groove combined with lymphedema. Although the results of treatment are very satisfactory, they require further investigation.